Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 15/20 | 0.60 |
| ▸ | HCRTR2 | O43614 | 15/20 | 0.60 |
| ▸ | TSPO | P30536 | 1/20 | 0.53 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.53 |
| ▸ | HTR2B | P41595 | 1/20 | 0.53 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.53 |
| ▸ | PIM1 | P11309 | 2/20 | 0.49 |
| ▸ | PIM3 | Q86V86 | 2/20 | 0.49 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.49 |
| ▸ | PADI4 | Q9UM07 | 2/20 | 0.44 |
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1030317 | 0.89 | HCRTR1 (0.49) | HCRTR1HCRTR2PADI4 | |
| SCHEMBL1029831 | 0.86 | HCRTR1 (0.51) | HCRTR1HCRTR2KDM1A | |
| SCHEMBL1032006 | 0.85 | HCRTR1 (0.56) | HCRTR1HCRTR2 | |
| SCHEMBL1027555 | 0.84 | HCRTR1 (0.62) | HCRTR1HCRTR2 | |
| SCHEMBL1029566 | 0.82 | HCRTR1 (0.60) | HCRTR1HCRTR2 | |
| SCHEMBL1029853 | 0.82 | HCRTR1 (0.59) | HCRTR1HCRTR2KDM1A | |
| SCHEMBL1028665 | 0.81 | HCRTR1 (0.49) | HCRTR1HCRTR2KDM1A | |
| SCHEMBL1028780 | 0.81 | HCRTR1 (0.57) | HCRTR1HCRTR2 | |
| SCHEMBL1029416 | 0.80 | HCRTR1 (0.51) | HCRTR1HCRTR2PADI4KDM1A | |
| SCHEMBL1671280 | 0.80 | HCRTR1 (0.71) | HCRTR1HCRTR2TSPOOPRK1HTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2094685-B1 | 3-HETEROARYL (AMINO OR AMIDO)-1- (BIPHENYL OR PHENYLTHIAZOLYL) CARBONYLPIPERDINE DERIVATIVES AS OREXIN RECEPTOR INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2011-01-19 | — | — | EP | claimed |
| US-20100069418-A1 | 3-HETEROARYL (AMINO OR AMIDO)-1-(BIPHENYL OR PHENYLTHIAZOLYL) CARBONYLPIPERIDINE DERIVATIVES AS OREXIN RECEPTOR INHIBITORS | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069418-A1 | 3-HETEROARYL (AMINO OR AMIDO)-1-(BIPHENYL OR PHENYLTHIAZOLYL) CARBONYLPIPERIDINE DERIVATIVES AS OREXIN RECEPTOR INHIBITORS | HCRTR1, HCRTR2, NPY1R | HCRTR1 1/4885HCRTR2 2/4885TSPO 216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.